General Information
Drug ID
DR00277
Drug Name
Ipratropium
Synonyms
(+-)-Ipratropine; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane; Aerodose; Aerovent; Apo-Ipravent; Apovent; Apovent (TN); Atronase; Atrovent; Atrovent (TN); Atrovent Aerosol; Atrovent Hfa; Atrovent Nasal; Bitrop; Disne-Asmol; Ipatropium Bromide; Ipratropium bromide; Ipravent; Ipvent; Kendral-Ipratropium; N-Isopropylatropine; Narilet; Rhinotrop; Rhinovent; Rinatec; Rinoberen; Rinovagos; Vagos; X8M; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
Drug Type
Small molecular drug
Indication Obstructive lung diseases [ICD11: CA22.Z] Approved [1]
Therapeutic Class
Bronchodilator Agents
Structure
3D MOL 2D MOL
Formula
C20H30NO3+
Canonical SMILES
CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C
InChI
InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1
InChIKey
OEXHQOGQTVQTAT-UHFFFAOYSA-N
CAS Number
CAS 60205-81-4
Pharmaceutical Properties Molecular Weight 332.5 Topological Polar Surface Area 46.5
Heavy Atom Count 24 Rotatable Bond Count 6
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 3
XLogP
2.6
PubChem CID
3746
PubChem SID
103127404 , 104170067 , 104304400 , 11466603 , 11467723 , 11486345 , 117575154 , 121362439 , 124886805 , 124968912 , 126407694 , 128799107 , 135650410 , 136350344 , 136959634 , 140035998 , 141999271 , 142186678 , 142719345 , 160857166 , 162879438 , 166233201 , 172080692 , 176484704 , 179148622 , 179694577 , 226395381 , 237172531 , 239293942 , 242128594 , 244502426 , 246151890 , 248499359 , 26756583 , 29222866 , 47509536 , 50070857 , 5243543 , 5243557 , 6951281 , 79331559 , 8152369 , 85209499 , 85788108
ChEBI ID
ChEBI:5956
TTD Drug ID
D0S0AS
DT(s) Transporting This Drug OCT-1 Transporter Info Organic cation transporter 1 Substrate [2]
OCTN1 Transporter Info Organic cation/carnitine transporter 1 Substrate [3]
OCTN2 Transporter Info Organic cation/carnitine transporter 2 Substrate [3]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OCT-1 Transporter Info Km = 9 microM Human embryonic kidney cells (HEK293)-OCT1 [2]
OCTN1 Transporter Info Km = 444 microM Human embryonic kidney cells (HEK293)-OCTN1 [3]
OCTN2 Transporter Info Km = 53 microM Human embryonic kidney cells (HEK293)-OCTN2 [3]
References
1 Ipratropium was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
3 Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.